- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03830502
Driving Factors of Decision Making for Prophylactic Salpingectomy Versus Tubal Ligation at the Time of Cesarean Section
Prophylactic (Opportunistic) salpingectomy is a cost-effective strategy recommended for reducing the risk of ovarian cancer at the time of gynecologic surgery in women who have completed childbearing. Similar evidence for cesarean section is growing. However, salpingectomy refers to the surgical removal of a female reproductive organ. Some women may have hesitations about salpingectomy with regard to religious concerns, reduced self-image, tubal reanastomosis or lack of knowledge.
The investigators aimed to explore the underlying factors that motivate women for either decisions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prophylactic and opportunistic bilateral salpingectomy is an increasing trend among surgeons and also proven as an effective risk-reducing method for ovarian cancer.
The investigators have experienced denials among women who were seeking tubal ligation as a sterilization procedure during cesarean section after a comprehensive counseling for prophylactic salpingectomy. Therefore, the investigators aimed to assess the driving factors of decision making for prophylactic salpingectomy or tubal ligation. It is planned to preoperatively have a non-validated questionnaire for the women after a detailed briefing.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bartin, Turkey
- Bartin State Hospital
-
Istanbul, Turkey
- Istanbul Sisli Hamidiye Etfal Training And Research Hospital, Health Sciences University
-
Istanbul, Turkey
- Medicalpark Gaziosmanpasa Hospital, Istinye University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women seeking for surgical sterilization during their cesarean section
- Elective and Category 2 or more planned cesarean sections
Exclusion Criteria:
- Clinical conditions that lead to planned cesarean hysterectomy such as placenta percreata
- History of ovarian cancer, previous chemotherapy or radiation
- Women who previously underwent sterilization
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Salpingectomy
Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
|
Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
|
Tubal ligation
Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
|
Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motivators for sterilization type
Time Frame: Evaluation at preoperative 32th gestational weeks
|
A non-validated data collection tool with open-ended questions assessing the factors behind the decision of salpingectomy or tubal ligation.
Data collection tool questions why patients choosed or refused salpingectomy in detail.
It is not a scale and does not have a range.
|
Evaluation at preoperative 32th gestational weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Murat Yassa, M.D., specialist
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- EtfalSalp
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sterilization, Tubal
-
EngenderHealthUnited States Agency for International Development (USAID); Tanzania Ministry... and other collaboratorsCompletedSterilization, TubalTanzania
-
Mayo ClinicCompletedTubal SterilizationUnited States
-
Jani JacquesRecruiting
-
Centre Hospitalier Universitaire de NīmesTerminated
-
Thomas Jefferson UniversityCompleted
-
Göteborg UniversityUmeå UniversityActive, not recruitingLaparoscopy | Ovarian Reserve | Salpingectomy | Sterilization TubalSweden
-
University of North Carolina, Chapel HillMedtronic - MITGCompletedPrevention & Control | Sterilization, Tubal | Salpingectomy | OvaryUnited States
-
University of PittsburghNational Institute on Minority Health and Health Disparities (NIMHD); University... and other collaboratorsActive, not recruitingContraception | Contraception Behavior | Women's Health | Reproductive Behavior | Tubal SterilizationUnited States
-
Alanya Alaaddin Keykubat UniversityCompletedSterilization, Tubal | Visual Analog Pain Scale
-
Shepherd Medical CompanyUnknown
Clinical Trials on Surgical sterilization
-
Cairo UniversityRecruiting
-
The Cleveland ClinicRecruiting
-
University of North Carolina, Chapel HillMedtronic - MITGCompletedPrevention & Control | Sterilization, Tubal | Salpingectomy | OvaryUnited States
-
BayerCompleted
-
Hologic, Inc.QST Consultations, Ltd.TerminatedReproductive SterilizationUnited States, Australia, Mexico
-
Tanta UniversityRecruitingContraception | Dysfunctional Uterine BleedingEgypt
-
Ain Shams UniversityNot yet recruitingDisinfectant Causing Toxic Effect
-
Yale UniversityPatient-Centered Outcomes Research Institute; University of California, Davis; Food and Drug Administration (FDA) and other collaboratorsCompletedContraception | Sterility, Female | Contraceptive Device; ComplicationsUnited States
-
EngenderHealthUnited States Agency for International Development (USAID); Tanzania Ministry... and other collaboratorsCompletedSterilization, TubalTanzania
-
Femasys Inc.Active, not recruiting